Canaccord Genuity Reiterates a 'Buy' on GenMark Diagnostics (GNMK); XT-8 Placements Paved the Way, Look for Continuation in 2011
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on GenMark Diagnostics (NASDAQ: GNMK), PT $8.
Canaccord analyst says, "Following what we view as ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Following what we view as ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
